Latest news with #MetforminHydrochloride
Business Standard
5 days ago
- Business
- Business Standard
Marksans Pharma gets regulatory nod for marketing type-2 diabetes medication in UK
Marksans Pharma said that its UK-based wholly owned subsidiary Relonchem has received marketing authorization for Metformin Hydrochloride oral solution product from UK Medicines & Healthcare Products Regulatory Agency. Metformin Hydrochloride is a widely prescribed medication used for the management of type-2 diabetes, particularly in patients who require oral liquid formulations due to difficulty in swallowing tablets. This regulatory approval would enable Marksans Pharma to market and distribute the said oral solution in the UK. Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergies. the company is marketing these products globally. The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24. The scrip rose 0.38% to currently trade at Rs 261.35 on the BSE.
Business Upturn
5 days ago
- Business
- Business Upturn
Marksans Pharma's subsidiary Relonchem gets UK MHRA approval for Metformin Hydrochloride Oral Solution
By Aman Shukla Published on May 30, 2025, 09:24 IST Marksans Pharma Limited has announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Metformin Hydrochloride 500mg/5ml Oral Solution. This regulatory approval enables Relonchem to market and distribute the product in the UK. Metformin Hydrochloride is a widely prescribed medication used for the management of type 2 diabetes, particularly in patients who require oral liquid formulations due to difficulty in swallowing tablets. In the exchange filing, the company shared, 'Marksans Pharma Limited (Reuters: Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Metformin Hydrochloride 500mg/ 5 ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.' This approval marks a significant milestone for Marksans Pharma as it continues to strengthen its presence in regulated markets like the UK. The company's focus on expanding its product portfolio with value-added generic formulations aligns with its strategic growth vision. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Standard
07-05-2025
- Business
- Business Standard
Trimax Biosciences achieves EDQM Certificate of Suitability for Metformin Hydrochloride
Sigachi Industries announced that Trimax Biosciences, a Sigachi Group Company has successfully achieved the Certificate of Suitability (CEP) for Metformin Hydrochloride from European Directorate for the Quality of Medicines & Health Care (EDQM). This milestone paves the way for Trimax to export this crucial Active Pharmaceutical Ingredient (API) to Europe and other CEP-accepting markets, further strengthening Sigachi's presence in highly regulated pharmaceutical markets. Powered by Capital Market - Live News
Business Upturn
07-05-2025
- Business
- Business Upturn
Sigachi Industries receives Certificate of Suitability for Metformin Hydrochloride from EDQM
By Aman Shukla Published on May 7, 2025, 12:48 IST Sigachi Industries Limited has recently received the Certificate of Suitability (CEP) for Metformin Hydrochloride from the European Directorate for the Quality of Medicines & Health Care (EDQM) on May 5, 2025. This certification underscores Sigachi's adherence to quality standards, regulatory compliance, and its readiness for global markets. Metformin Hydrochloride, a common medication for managing type 2 diabetes, is projected to reach a market value of USD 386.91 million by 2030, growing at a compound annual growth rate (CAGR) of approximately 4.7%. Several Metformin-based Fixed Dose Combinations (FDCs) have already been approved by the U.S. Food and Drug Administration (USFDA), including products like Glucovance, Actoplus Met, Janumet, and others. These approvals highlight the recognized role of Metformin-based therapies in diabetes care. The CEP certification for Metformin Hydrochloride is in line with Sigachi's ongoing strategy to strengthen its presence in regulated markets, ensuring the company meets the European Union's stringent safety, efficacy, and Good Manufacturing Practice (GMP) requirements. Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited, commented, 'This achievement aligns perfectly with our vision of expanding into highly regulated markets and strengthen our position in the global pharmaceutical industry. With the rising demand for Metformin-based therapies, Sigachi is committed to leveraging its R&D expertise and state-of-the-art facilities to deliver pharmaceutical solutions that meet international standards and address the dynamic needs of the healthcare sector.' Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
15-04-2025
- Business
- Yahoo
Vistin Pharma ASA: Invitation to Q1 2025 conference call
Oslo, Norway, 15 April 2025 Vistin Pharma ASA (VISTN) will release its first quarter results on Friday 25th of April 2025. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The first quarter conference call will be available via web and audio through the following access points: Webcast: Telephone conference (online registration): ***** For further information, please contact: Alexander KarlsenCFO+47 About Vistin Pharma | Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø. Sign in to access your portfolio
